U.S. drugmaker Bristol-Myers Squibb Co said on Thursday that it received a subpoena from securities regulators regarding its sales and marketing practices in various foreign countries. Bristol-Myers, in a filing, said it received the subpoena from the U.S. Securities and Exchange Commission (SEC) last month in connection with an investigation under the Foreign Corrupt Practices Act (FCPA). The company said it was cooperating with the government in its investigation. It declined to divulge what countries or products were involved in the probe or to give any details beyond the brief statement in the filing.
